Acadia (ACAD) Form 144 Notifies 22,000-Share Insider Sale

Rhea-AI Filing Summary

Acadia Pharmaceuticals (ACAD) filing a Form 144 to notify a proposed sale of securities. The notice identifies 22,000 shares of common stock to be sold through Piper Sandler & Co. on or about 08/18/2025, with an aggregate market value of $557,260.00. The filing shows the shares were acquired as compensation from the issuer on 11/17/2023 and payment was recorded on that date. The filing lists total shares outstanding as 168,712,220. Several standard filer and issuer identification fields in the form are blank, and no name is provided for the person on whose account the sale will occur.

Insights

Securities Compliance Analyst

TL;DR: Routine Form 144 notice for a director/insider sale with standard brokerage execution; no material new disclosures.

The filing documents a proposed sale of 22,000 common shares via Piper Sandler with an indicated market value of $557,260 and an approximate sale date of 08/18/2025. The shares were acquired as compensation on 11/17/2023. The notice lacks identifying filer and issuer contact details and does not name the selling person, which is an omission for transparency though not necessarily a compliance fatality if the full form elsewhere contains those details. No recent sales in the past three months are reported.

Corporate Governance Expert

TL;DR: Administrative disclosure of a planned insider sale; impact appears neutral absent other context.

The document indicates an insider-originated sale notification rather than a company action. Key facts—quantity (22,000 shares), acquisition as compensation (11/17/2023), broker (Piper Sandler), and planned sale date (08/18/2025)—are clearly recorded. The absence of the seller's name in the visible excerpt reduces standalone clarity; investors relying on issuer identity should consult the full filing record for complete names and signatures.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Piper Sandler & Co Inc 350 N 5th St Ste 1000 Minneapolis MN 55402	22000	557260.00	168712220	08/18/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	11/17/2023	Compensation	Issuer			22000	11/17/2023	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What securities does the ACAD Form 144 propose to sell?

The notice proposes the sale of 22,000 shares of ACAD common stock.

When is the proposed sale date listed on the ACAD Form 144?

The approximate date of sale is listed as 08/18/2025.

What is the aggregate market value of the shares to be sold in the ACAD filing?

The filing shows an aggregate market value of $557,260.00.

How were the shares being sold acquired according to the Form 144?

The shares were acquired as compensation from the issuer on 11/17/2023.

Which broker is named to execute the sale in the ACAD Form 144?

The broker listed is Piper Sandler & Co. Inc.

Does the filing list recent sales by the seller in the past three months?

The filing states "Nothing to Report" for securities sold during the past three months.

Is the identity of the person on whose account the securities will be sold provided in this excerpt?

No. The visible excerpt does not provide the name of the person for whose account the securities are to be sold.